Christopher Marai
Stock Analyst at Nomura
(2.50)
# 2,158
Out of 4,792 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $4.92 | +19,412.20% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $46.50 | -29.03% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $3.41 | +2,543.17% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $262.16 | -71.77% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $3.11 | +414.47% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $130.71 | +199.90% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.50 | +2,166.67% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $58.61 | +292.42% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $12.46 | -3.69% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $11.32 | +67.84% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $1.20 | +3,483.33% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $4.92
Upside: +19,412.20%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $46.50
Upside: -29.03%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $3.41
Upside: +2,543.17%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $262.16
Upside: -71.77%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $3.11
Upside: +414.47%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $130.71
Upside: +199.90%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.50
Upside: +2,166.67%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $58.61
Upside: +292.42%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $12.46
Upside: -3.69%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $11.32
Upside: +67.84%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $1.20
Upside: +3,483.33%